Porcine FVIII (pFVIII) was introduced as a first-line therapy to control bleeding in AHA-related illnesses in the 1980s, especially in patients with high-titre inhibitors [9], thanks to the reduced cross-reactivity with human autoantibodies, which was significantly lower than with alloantibodies [10]. This evidence concerns the gene F8 and autoimmune hemolytic anemia.